Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Join Channel
Consolidated Standalone

Novartis

₹1066.2 12.4 | 1.2%

Market Cap ₹2633 Cr.

Stock P/E 30.9

P/B 3.6

Current Price ₹1066.2

Book Value ₹ 295.2

Face Value 5

52W High ₹1224

Dividend Yield 2.34%

52W Low ₹ 600

Edit Ratio

Novartis Research see more...

Overview Inc. Year: 1947Industry: Trading

Novartis India Ltd manufactures tablets, drugs and allied merchandise. The Company is engaged in the wholesale of pharmaceuticals and clinical goods. The Company makes a speciality of over three divisions, along with prescription drugs, eye care and ordinary drug treatments. The Pharmaceuticals segment consists of a portfolio of prescription drug treatments, that are given to patients via healthcare specialists. Its Pharmaceutical business is focused on bone and pain, calcium portfolio, gynaecology and neurosciences. The prescribed drugs division is engaged within the improvement and commercialisation in oncology, primary care and distinctiveness medicines. The Generics section contains retail generics products. The enterprise unit makes a speciality of the healing segments, such as anti-tuberculosis (TB), anti-dysfunctional uterine bleeding (DUB (Gynecology)), antihistamines, antibiotics, anti-ulcerants, anti-diabetes and cardiovascular. The Company's geographical segments consist in India and other Countries.

Read More..

Novartis Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Novartis Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 99 98 121 102 80 76 91 79 85 81
Other Income 6 14 27 7 8 16 12 17 22 10
Total Income 105 113 147 108 89 93 103 96 107 92
Total Expenditure 92 93 89 85 73 67 73 62 65 70
Operating Profit 13 20 58 23 16 26 30 34 42 22
Interest 1 0 1 0 0 0 0 1 0 0
Depreciation 3 1 1 1 1 2 2 1 0 0
Exceptional Income / Expenses 0 -50 0 0 0 0 0 0 0 0
Profit Before Tax 8 -31 57 21 14 23 28 32 41 21
Provision for Tax 2 -8 4 3 7 -2 8 9 15 7
Profit After Tax 6 -23 52 18 8 25 20 24 27 15
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 6 -23 52 18 8 25 20 24 27 15
Adjusted Earnings Per Share 2.6 -9.5 21.2 7.4 3.1 10.1 8.2 9.6 10.8 5.9

Novartis Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 903 862 873 690 656 564 491 438 381 400 379 336
Other Income 84 97 112 245 72 174 78 36 34 34 58 61
Total Income 988 959 985 934 728 738 569 475 416 433 437 398
Total Expenditure 814 866 881 659 632 572 479 427 356 373 314 270
Operating Profit 173 94 104 275 96 166 91 48 60 60 123 128
Interest 0 0 0 0 1 6 2 6 8 5 2 1
Depreciation 4 4 4 3 4 3 3 13 12 10 6 3
Exceptional Income / Expenses 0 0 -6 0 0 0 0 0 0 -50 0 0
Profit Before Tax 169 90 93 272 92 158 86 29 40 -4 115 122
Provision for Tax 50 -9 14 73 35 79 34 19 19 -0 12 39
Profit After Tax 120 99 79 198 57 78 52 10 21 -4 103 86
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 120 99 79 198 57 78 52 10 21 -4 103 86
Adjusted Earnings Per Share 37.5 30.8 24.8 62 20.3 31.8 21 4.1 8.5 -1.5 41.9 34.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -5% -5% -8% -8%
Operating Profit CAGR 105% 37% -6% -3%
PAT CAGR 0% 118% 6% -2%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 70% 18% 9% 9%
ROE Average 14% 5% 5% 8%
ROCE Average 16% 8% 8% 12%

Novartis Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 900 961 1002 1194 920 734 759 721 711 692 776
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 560 586 697 26 828 898 891 99 1131 984 1008
Total Current Liabilities 493 459 362 204 323 482 367 417 357 334 268
Total Liabilities 1953 2006 2060 1425 2070 2113 2018 1237 2199 2010 2052
Fixed Assets 10 8 9 6 6 5 15 76 64 24 19
Other Non-Current Assets 629 690 837 154 953 1004 1014 163 1213 1160 1246
Total Current Assets 1314 1308 1215 1264 1111 1104 989 997 922 826 786
Total Assets 1953 2006 2060 1425 2070 2113 2018 1237 2199 2010 2052

Novartis Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 82 36 15 637 25 76 38 88 79 68 158
Cash Flow from Operating Activities 7 -5 -60 57 -41 161 -194 -23 -69 39 45
Cash Flow from Investing Activities -16 22 719 -630 424 69 274 56 95 87 -153
Cash Flow from Financing Activities -37 -38 -38 -39 -332 -268 -30 -41 -37 -36 -30
Net Cash Inflow / Outflow -46 -20 622 -612 51 -38 50 -9 -11 90 -139
Closing Cash & Cash Equivalent 36 15 637 25 76 38 88 79 68 158 19

Novartis Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 37.46 30.83 24.75 62.04 20.33 31.75 20.98 4.08 8.47 -1.51 41.88
CEPS(Rs) 38.59 31.97 26.01 63.14 21.61 32.78 22.26 9.41 13.4 2.4 44.34
DPS(Rs) 10 10 10 10 10 10 10 10 10 10 47.5
Book NAV/Share(Rs) 281.67 300.8 313.51 375.63 329.45 299.77 309.34 293.36 289.36 281.17 314.3
Core EBITDA Margin(%) 9.8 -0.4 -0.89 4.47 3.74 -1.2 2.06 2.2 5.66 5.5 14.15
EBIT Margin(%) 18.71 10.42 10.69 39.41 14.09 23.82 14.82 6.58 10.52 0.21 25.47
Pre Tax Margin(%) 18.69 10.39 10.66 39.38 13.98 23.01 14.55 5.38 8.82 -0.78 25.09
PAT Margin (%) 13.21 11.39 9.05 28.74 8.72 11.45 8.78 1.89 4.61 -0.76 22.48
Cash Profit Margin (%) 13.6 11.81 9.51 29.25 9.27 11.82 9.32 4.36 7.29 1.22 23.79
ROA(%) 6.39 4.98 3.89 11.38 3.27 3.75 2.51 0.62 1.22 -0.18 5.09
ROE(%) 13.94 10.59 8.06 18.01 5.38 9.4 6.89 1.36 2.91 -0.53 14.07
ROCE(%) 19.74 9.69 9.52 24.77 8.75 19.72 11.7 4.73 6.67 0.14 15.96
Receivable days 30.68 33.71 33.46 35.2 25.31 22.59 27.72 28.5 30.7 31.23 32.03
Inventory Days 38.08 45.08 42.48 45.59 44.47 38.41 36.25 40.83 42.89 39.38 44.36
Payable days 108.04 107.2 105.65 104.65 85.19 133.31 181.45 164.16 159.09 130.52 119.32
PER(x) 15.98 14.42 22.72 10.45 33.26 19.28 32.69 122.97 65.18 0 13.5
Price/Book(x) 2.13 1.48 1.79 1.73 2.05 2.04 2.22 1.71 1.91 2.1 1.8
Dividend Yield(%) 1.67 2.25 1.78 1.54 1.48 1.63 1.46 1.99 1.81 1.69 8.4
EV/Net Sales(x) 2.08 1.63 1.1 1.37 1.66 1.31 2.2 1.5 2.26 2.35 2.22
EV/Core EBITDA(x) 10.82 14.96 9.24 3.44 11.32 4.45 11.93 13.65 14.42 15.58 6.81
Net Sales Growth(%) 7 -4.55 1.29 -21.02 -4.86 -14.07 -12.98 -10.69 -12.98 4.86 -5.28
EBIT Growth(%) -24.68 -46.85 3.63 190.97 -66 76.37 -46.42 -59.9 36.23 -97.88 0
PAT Growth(%) -21.24 -17.71 -19.71 150.65 -71.14 36.95 -33.93 -80.53 107.34 -117.8 2878.49
EPS Growth(%) -21.24 -17.71 -19.71 150.65 -67.23 56.14 -33.93 -80.53 107.34 -117.8 2878.48
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 2.67 2.85 3.36 6.18 3.44 2.29 2.69 2.39 2.58 2.47 2.93
Quick Ratio(x) 2.44 2.62 3.08 5.99 3.17 2.17 2.53 2.25 2.45 2.3 2.73
Interest Cover(x) 771.09 333.96 444.95 1294.67 128.4 29.48 54.94 5.48 6.21 0.21 66.93
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Novartis Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 70.68 70.68 70.68 70.68 70.68 70.68 70.68 70.68 70.68 70.68
FII 0.09 0.12 0.14 0.17 0.17 0.17 0.24 0.32 0.19 0.19
DII 0.78 0.78 0.78 0.78 0.78 0.78 0.75 0.52 0.52 0.52
Public 28.46 28.43 28.41 28.38 28.38 28.38 28.33 28.48 28.61 28.61
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 130.52 to 119.32days.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 5% over the last 3 years.
  • Stock is trading at 3.6 times its book value.
  • The company has delivered a poor profit growth of 5% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Novartis News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!